scispace - formally typeset
G

Glenn Dranoff

Researcher at Harvard University

Publications -  8
Citations -  3587

Glenn Dranoff is an academic researcher from Harvard University. The author has contributed to research in topics: Immune system & Cancer. The author has an hindex of 6, co-authored 8 publications receiving 3045 citations. Previous affiliations of Glenn Dranoff include Brigham and Women's Hospital.

Papers
More filters
Journal ArticleDOI

Cancer immunotherapy comes of age

TL;DR: In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
Journal ArticleDOI

Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

TL;DR: A central role for LMP1 in the surveillance and transformation of EBV-infected B cells in vivo is indicated, a preclinical model for B cell lymphomagenesis in immunosuppressed patients is established, and a new therapeutic approach is validated.
Journal ArticleDOI

IAP inhibitors enhance co-stimulation to promote tumor immunity

TL;DR: It is found that IAP antagonists can augment human and mouse T cell responses to physiologically relevant stimuli and suggest that targeting IAPs using small molecule antagonists may be a strategy for developing novel immunomodulating therapies against cancer.
Journal ArticleDOI

A dual role for the immune response in a mouse model of inflammation-associated lung cancer

TL;DR: A model whereby cytokine deficiency leads to oncogenic inflammation that combines with defective antitumor immunity to promote lung tumor formation is suggested, representing a unique system for studying the role of the immune system in lung tumor development.
Journal ArticleDOI

Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis

TL;DR: Together, these results delineate an immunotherapy-induced host response that broadly targets the angiogenic network in the tumor microenvironment.